AUCTA
GenericsAUCTA is a generic drug manufacturer focused on Neurology, Infectious Disease, Respiratory. Key products include MOTPOLY XR.
AUCTA's Key Drugs
AUCTA's core commercial portfolio centers on ZELVYSIA, MOTPOLY XR, VIGADRONE, spanning Neurology and Infectious Disease — its most strategically important drugs approved in the last 15 years.
Hyperphenylalaninemia
Partial-Onset Seizures
Complex Partial Seizures
Duchenne Muscular Dystrophy
AUCTA's Recent FDA Approvals
New NDA/BLA approvals for AUCTA over the last two years — novel drugs only, excluding generics and label supplements.
AUCTA's Therapeutic Areas
AUCTA's approved drugs and pipeline span 3 therapeutic areas, led by Neurology and Infectious Disease, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
AUCTA's Top Competitors
AUCTA's closest competitors by therapeutic-area and drug-target overlap include GE HEALTHCARE, Pfizer, and LEDERLE. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
AUCTA Pipeline Snapshot
Active clinical trials for AUCTA across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • ZELVYSIA leads revenue
- • 4 key drugs tracked
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (4)
Discontinued (0)
Company Info
- First Approval
- 2018-06-21
- Latest
- 2026-06-02
- Applications
- 8